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Widespread remodeling of the transcriptome is a
signature of cancer; however, little is known about
the post-transcriptional regulatory factors, including
RNA-binding proteins (RBPs) that regulate mRNA
stability, and the extent to which RBPs contribute
to cancer-associated pathways. Here, by modeling
the global change in gene expression based on the
effect of sequence-specific RBPs on mRNA stability,
we show that RBP-mediated stability programs are
recurrently deregulated in cancerous tissues. Partic-
ularly, we uncovered several RBPs that contribute to
the abnormal transcriptome of renal cell carcinoma
(RCC), including PCBP2, ESRP2, andMBNL2.Modu-
lation of these proteins in cancer cell lines alters the
expression of pathways that are central to the dis-
ease and highlights RBPs as driving master regula-
tors of RCC transcriptome. This study presents a
framework for the screening of RBP activities based
on computational modeling of mRNA stability pro-
grams in cancer and highlights the role of post-tran-
scriptional gene dysregulation in RCC.
INTRODUCTION
Cancer is a complex disorder, with a large array ofmolecular fac-
tors involved. Global deregulation of genes is a hallmark of can-C
This is an open access article undcer cells, and a large number of the diagnostic, prognostic, and
therapeutic approaches target ‘‘master regulators’’ of gene
expression or their downstream effectors (Goolam et al., 2016;
Kim and Roberts, 2016; Perera et al., 2015). Nevertheless, unlike
extensive studies on diverse molecular factors involved in tran-
scriptional gene regulation, such as aberrations involving tran-
scription factors (TFs) or epigenetic patterns, our knowledge of
the mechanisms underlying post-transcriptional gene deregula-
tion in cancer is scarce. RNA-binding proteins (RBPs), as key
factors that modulate the stability and splicing of thousands of
mRNAs (Gerstberger et al., 2014), play central roles in post-tran-
scriptional gene regulation. Previous studies have linked a few
RBPs with transcriptome remodeling and disease progression
in cancer. For example, TARBP2 (Goodarzi et al., 2014) and
NELFE (Dang et al., 2017) have recently been identified as onco-
genic RBPs whose abnormal activation results in the progres-
sion of breast and hepatocellular carcinomas, respectively, by
dysregulating the stability of their target mRNA. Likewise overex-
pression of SNRPB leads to abnormal splicing of many genes
involved in DNA repair and chromatin remodeling pathways,
thereby contributing to enhanced cell proliferation in glioblas-
toma (Correa et al., 2016).
However, a systematic interrogation of RBP-mediated regula-
tory programs in cancer and the extent to which they shape the
cancer gene expression signature has not been performed,
despite evidence for widespread dysregulation of these proteins
in cancer (Kechavarzi and Janga, 2014). A recent analysis of eu-
karyotic RBPs has provided a regulatory model that links the
binding of 35 human RBPs to the decay rate of their target
mRNAs (Ray et al., 2013). This model identifies high-confidenceell Reports 23, 1639–1650, May 8, 2018 ª 2018 The Authors. 1639
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Figure 1. Inferring Dysregulated Post-tran-
scriptional Programs from ccRCC Expres-
sion Data
(A) Schematic representation of inferring RBP
activities by combining the stability code (Ray
et al., 2013) with gene expression data. The plus
(+) signs represent stabilizing RBPs, and the
minus () signs stand for destabilizing RBPs.
(B) The inferred activity profiles of RBPs in ccRCC
tumors. Each row represents one patient from the
CAGEKID cohort (Scelo et al., 2014), and each
column represents one RBP. Plus (+) and minus
() signs denote RBPs that stabilize or destabilize
their targets, respectively. The color gradient
corresponds to the inferred ccRCC-associated
activity change (Z score obtained by boot-
strapping; see Experimental Procedures). Red
denotes increased activity of RBP in ccRCC tu-
mor relative to matching normal tissue, and blue
denotes decreased activity.
See also Figure S1.regulatory targets of each RBP, including mRNAs that have a
functional RBP binding site at their 30 UTRs, and indicates
whether the binding of each RBP ‘‘stabilizes’’ or ‘‘destabilizes’’
its regulatory targets. Here, using this model, we present a gen-
eral computational framework for analyzing post-transcriptional
gene regulatory programs in cancer to identify key RBPs whose
aberrant function plays a central role in the establishment of can-
cer-associated expression signatures.
We applied our method to gene expression profiles of clear
cell renal cell carcinoma (ccRCC), which is the most common
type of kidney cancer. The incidence rate of ccRCC is increasing
worldwide, and its metastatic form is resistant to chemotherapy
and radiotherapies (Capitanio and Montorsi, 2016). A hallmark of
ccRCC is dramatic dysregulation of the transcriptome, which is
partly mediated by transcriptional programs governed by the
hypoxia-inducible transcription factor (HIF) and the malfunction
of the epigenome machinery (Riazalhosseini and Lathrop,
2016). However, our understanding of the mechanisms that un-
derlie the post-transcriptional gene regulation in ccRCC is very
limited. We show that RBPs contribute significantly to the regu-
lation of ccRCC transcriptome throughmodulation of mRNA sta-
bility, and we uncover key RBPs that regulate central ccRCC
pathways.1640 Cell Reports 23, 1639–1650, May 8, 2018RESULTS
Widespread Dysregulation of Post-
Transcriptional Regulatory
Programs in ccRCC
To identify RBP stability programs that
are dysregulated in ccRCC, we used
the RNA sequencing (RNA-seq) profiles
of tumor and patient-matched normal
tissue sample pairs from 45 ccRCC pa-
tients in the Cancer Genomics of the
Kidney (CAGEKID) cohort (Scelo et al.,
2014). These expression profiles quanti-
tatively measure the extent of increaseor decrease in the abundance of each mRNA in tumor cells
compared to matching normal kidney tissue. We modeled
the abundance of each mRNA as a function of the combinato-
rial effect of RBPs that bind to that mRNA (see Experimental
Procedures), with the mRNA-RBP interactions derived from a
previously reported ‘‘high-confidence’’ stability network (Ray
et al., 2013). Following previously described methods for
modeling gene regulatory networks (Lee and Bussemaker,
2010), we assumed that, in the logarithmic scale, the differen-
tial stability of each mRNA reflects the additive effect of the dif-
ferential activity of RBPs that bind to that mRNA (Figure 1A). In
this model, an increase in the ‘‘activity’’ of a stabilizing RBP or
a decrease in the activity of a destabilizing RBP can result in an
increase in the abundance of their target mRNAs. Conversely,
a decrease in the activity of a stabilizing RBP or an increase in
the activity of a destabilizing RBP can lead to a decrease in the
abundance of their target mRNAs. By combining this model
with ccRCC gene expression data, we predicted the change
in the activity of RBPs based on the change in the abundance
of their target mRNAs (Figure 1A). This model only considers
post-transcriptional regulation by RBPs and, therefore, can
only partially explain the changes in mRNA abundance.
Despite this limitation, as we will show here, this model
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Figure 2. Orthogonal Information Supports
the Inferred ccRCC-Associated RBP Activ-
ity Levels
(A) Correlation of the inferred activity profile of
each RBP with its mRNA abundance across the
CAGEKID cohort. See Figure S2 for individual
scatterplots for each RBP.
(B) Overall change in inferred activity versus
mRNA expression of RBPs. Each dot represents
one RBP. The x axis corresponds to the t score of
difference of mRNA abundance in tumor versus
matching normal tissues (paired t test of log-
transformed expression). The y axis corresponds
to the t score of inferred ccRCC-associated ac-
tivity changes: a positive value indicates that the
average of the corresponding column in Figure 1B
is above zero, and a negative value indicates that
the average is below zero. Circles with black
borders represent RBPs that have a motif that is
based on direct experimental evidence or based
on an analysis of a human paralog with >80%
sequence similarity at the RNA-binding domain
(Ray et al., 2013).
(C) Overlap of the RBPswhose stability targets are
significantly dysregulated (FDR < 0.01, t test of
average inferred RBP activity change) and RBPs
whose splicing targets are significantly enriched
for isoform switch events (FDR < 0.01, Fisher’s
exact test).
(D) Comparison of the inferred activity of RBPs, based on the stability code analysis, between CAGEKID and TCGA cohorts. The axes show the t statistic for
average inferred RBP activity change between tumor and normal tissue. RBPs with a direct motif or with a motif that is derived from a human paralog with >80%
sequence similarity (Ray et al., 2013) are shown. The circle size denotes the number of stability targets for each RBP.
See also Figure S2 and Table S1.successfully identifies drivers of aberrant post-transcriptional
regulatory programs.
We observed that regulatory programs that are associated
with a large number of RBPs appear to be dysregulated in
ccRCC, based on the predicted activity levels of RBPs in
different patients (Figure 1B). To examine whether these esti-
mates are confounded by transcription, we also used a recent
approach for deconvolution of transcription and decay rates
based on the intronic and exonic reads in the RNA-seq data
(Alkallas et al., 2017). The RBP activities that were inferred
from estimated mRNA stability profiles were highly consistent
with the activities that we inferred from mRNA abundances
(Figure S1), suggesting that our inferences are not confounded
by the impact of transcription. These activity patterns were
different across patients for some of the RBPs, which may
reflect the inter-individual heterogeneity in ccRCC (Figure 1B).
As expected, the predicted activity levels for a majority of
RBPs correlated with the RBP mRNA abundances across indi-
viduals (p < 4 3 107, t test for average Pearson correlation;
Figures 2A and S2). Furthermore, the overall increase or
decrease of activity of RBPs in ccRCC was consistent with their
overall up- or downregulation at the mRNA level (r = 0.4,
p < 0.01; Figure 2B). These results suggest that the predicted
RBP activity levels are, in part, functional consequences of
the change in the expression of RBPs and can serve to predict
RBPs whose dysregulation govern abnormal post-transcrip-
tional gene regulation in ccRCC.Identification and Validation of Recurrent Dysregulated
Post-Transcriptional Programs
We used multiple orthogonal sources of information to further
validate our prediction of the RBPs that contribute to the aber-
rant post-transcriptional gene regulation in ccRCC. First, we
reasoned that, for RBPs that have a dual role in regulating
mRNA stability and splicing (Ray et al., 2013), a change in the
RBP activity should, at the same time, affect the stability of the
mRNAs that have a binding site for that RBP in their 30 UTRs,
as well as the splicing of the mRNAs with a binding site near their
exon-intron junctions. We identified RBPs whose splicing tar-
gets, as defined previously based on the presence of binding
sites near exon-intron junctions of alternatively spliced exons
(Ray et al., 2013), overlap significantly with ccRCC-associated
‘‘isoform switch events’’ (Scelo et al., 2014) (Table S1). These
switch events represent changes in the identity of the most
abundant spliced variant of a given gene in tumors compared
to patient-matched normal tissue. Of the 10 RBPs whose
splicing target set had a significant (false discovery rate
[FDR] < 0.05) overlap with the ccRCC isoform switch events,
six RBPs were also among the ones whose stability programs
were dysregulated (Figure 2C), in agreement with the previously
observed dual role of these RBPs in regulating both mRNA
splicing and stability (Ray et al., 2013).
Next, we examined the reproducibility of RBP activity infer-
ence across different ccRCC datasets. For this, we used the
expression profiles of 72matching pairs of ccRCC tumor-normalCell Reports 23, 1639–1650, May 8, 2018 1641
tissues from The Cancer Genome Atlas (TCGA) dataset (Cancer
Genome Atlas Research Network, 2013) and inferred the change
in the RBP activity levels in tumor versus normal samples of each
patient. We observed a strong correlation in the ccRCC-associ-
ated change in RBP activity levels between the CAGEKID and
TCGA cohorts (r = 0.81 for RBPs with a direct motif or a motif
derived from a highly similar human paralog, p < 2 3 1010; Fig-
ure 2D), confirming that our measurements are not dataset
specific.
This comparative analysis revealedmultiple RBPswith consis-
tently large up- or downregulation of activity levels in both the
CAGEKID and TCGA cohorts (Figure 2D; Table S1). In this
work, we focus on three RBPs with the largest and most repro-
ducible dysregulation of cancer-associated activity: ESRP2,
which showed the greatest decrease in activity; and MBNL2
and PCBP2, which showed the largest increase in activity.
Modulation of RBP Levels Supports Their Role in
Remodeling ccRCC Transcriptome
We further investigated the roles of ESRP2, PCBP2, and MBNL2
in remodeling the ccRCC transcriptome and the potential contri-
bution to malignancy by analyzing pathways affected by their
modulation, along with associated cellular functions. For this
purpose, we performed an integrated analysis of ccRCC gene
expression profiles and the transcriptomes of the cells that
were specifically deficient (through RNAi) for candidate RBPs.
Overall, for all the three RBPs, we observed a significant agree-
ment between the transcriptome response that RBP knockdown
triggered in the cell and what we expected based on our analysis
of ccRCC expression profiles, as described in the following
sections.
Modulation of ESRP2 Partially Recreates the
Transcriptome Changes in ccRCC
In line with the reduced activity of ESRP2 that we had identified in
both CAGEKID and TCGA datasets (Figure 2D), we observed
that the mRNA of ESRP2 is significantly downregulated in tumor
tissues in both cohorts (Figure 3A). Likewise, we detected much
higher expression levels of ESRP2 in normal primary renal prox-
imal tubule epithelial cells (PRPTECs) compared to several
ccRCC cell lines (Figure 3B). Accordingly, we knocked down
the ESRP2 gene in PRPTECs using two independent short
hairpin RNAs (shRNAs) (Figure 3C) and investigated the changes
of the transcriptome using RNA-seq. We observed widespread
and reproducible remodeling of the PRPTEC transcriptome as
a result of ESRP2 knockdown (Figures 3D and S3A); specifically,
we observed overall upregulation of the stability of the mRNAs
that have potential ESRP2 binding sites in their 30 UTRs, partic-
ularly for genes that are also upregulated in ccRCC tumors at the
stability level (Figure S3B). This observation is consistent with the
previously suggested role of ESRP2 in destabilizing its target
mRNAs (Ray et al., 2013), suggesting that downregulation of
ESRP2 in ccRCC tumors leads to upregulation of its targets.
We note that the effect of this deregulation may spread beyond
the direct targets of ESRP2 and lead to the upregulation and
downregulation of downstream genes. Consistent with this
notion, we observed dysregulation of the mRNA abundances
for a considerable number of biological processes and genes af-1642 Cell Reports 23, 1639–1650, May 8, 2018ter ESRP2 knockdown, which largely mirrored those that are
dysregulated in ccRCC tumors (Figure 3E). These included upre-
gulation of components of extracellular matrix (ECM), in line with
previous reports on an increased deposition of ECM in cancer
(reviewed by Gilkes et al., 2014), as well as downregulation of
processes related to mitochondrial metabolism and oxidative
phosphorylation, which are most often downregulated in ccRCC
tumors (Cancer Genome Atlas Research Network, 2013; Scelo
et al., 2014) (Figure 3F). We further validated upregulation of
COL1A1, a major component of ECM, at the protein level upon
ESRP2 depletion (Figure 3G). These findings further support
the role of ESRP2 deficiency in the abnormal activity of
ccRCC-associated pathways.
PCBP2 Positively Regulates Cell-Cycle Progression
Our analysis of activity patterns of RBPs also highlighted PCBP2
as one of the RBPswith themost elevated activity in ccRCC (Fig-
ure 2D). Interestingly, however, analysis of the PCBP2 mRNA
levels did not show a significant change in the tumors as
compared to normal samples in any of the two cohorts (Fig-
ure 4A). To rectify this apparent discrepancy, we set out to
directly measure the protein abundance of PCBP2 in tumor
and normal tissues of an independent cohort of ccRCC patients,
using tissue microarrays (TMAs) (Xu et al., 2013). Through immu-
nohistochemistry (IHC) analysis, we were able to measure the
abundance of PCBP2 in a panel of 58 morphologically normal
and 77 tumor tissue samples from ccRCC patients. Our results
from these experiments revealed that PCBP2 shows a strong
increase in abundance in tumor cells (5.8-fold increase,
p < 7 3 108; Figures 4B and 4C), in agreement with the pre-
dicted increase in its activity levels. These findings suggested
that upregulation of PCBP2 occurs at post-transcriptional level.
Indeed, our analysis of a previously published dataset (Loayza-
Puch et al., 2016) revealed a strong increase (4.9-fold) in ribo-
some occupancy of PCBP2 mRNA in a ccRCC tumor compared
to matching normal kidney tissue, in line with translational upre-
gulation of PCBP2 in tumors (Figure S4A).
To gain insight about the functional significance of PCPB2
abnormal activation in ccRCC, we explored cellular pathways
whose activity is influenced by PCPB2. We observed that, in
HepG2 cells, whose gene expression profile is correlated with
that of common ccRCC cell lines (Figure S4B), PCBP2 knock-
down induces a change in the transcriptome that is in the
opposite direction of the transcriptome remodeling in ccRCC
(r =0.07, p < 63 1024; Figure 4D; PCBP2-knockdown expres-
sion data are from the ENCODE Project Consortium [2012]).
Furthermore, genes that are downregulated after PCBP2 knock-
down are enriched for pathways that are relevant to cell prolifer-
ation in cancer, including cell cycle and related pathways
(Figure 4E). The genes in these pathways are also correlated
with inferred PCBP2 activity levels across the 45 CAGEKID sam-
ples (p < 43 105, t test for average Pearson correlation), but not
with PCBP2mRNA levels (Figure 4F), further highlighting the bio-
logical relevance of the inferred activity levels in contrast to
mRNA abundance for this RBP. In line with these results, we
observed G1 cell-cycle arrest upon the inhibition of PCBP2
through RNAi in 786-O and A-498 renal cancer cell lines (Figures
4G and 4H), which resulted in reduced cell viability and induction
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Figure 3. ESRP2 Deficiency Results in Dys-
regulation of ECM and Metabolic Pathways
(A) The ccRCC-associated mRNA abundance
change for ESRP2. The y axis corresponds to a
p value obtained from paired t test of mRNA
abundance between ccRCC tumors and match-
ing normal tissue, either from the CAGEKID cohort
(light gray) or the TCGA cohort (dark gray). The
p value of upregulation is shown above baseline,
and downregulation is shown below baseline, in
logarithmic scale.
(B) Comparison of the abundance of ESRP2
mRNA between normal primary renal proximal
tubule epithelial cells (PRPTECs) and seven
common cell line models of RCC, measured by
qRT-PCR.
(C) ESRP2mRNA abundance, measured by qRT-
PCR, in PRPTECs infected with a control shRNA
(Ctrl) or with two different shRNAs that specifically
target ESRP2.
(D) Widespread and reproducible change in
mRNA abundance as a result of ESRP2 knock-
down in PRPTECs. Each row represents one
gene, and each column represents either trans-
fection of PRPTECs with an ESRP2-specific
shRNA or with a control shRNA. Only genes that
had at least 10 reads in each RNA-seq dataset
and showed a minimum of 20% increase or
decrease of expression in both of the ESRP2
shRNA transfections compared to both of the
control shRNA transfections are included. A total
of 667 genes match these criteria for reproducible
up-/downregulation of expression; the probability
of observing this number of reproducible changes
by chance is 4 3 106 based on permutation
of expression fold-change values within each
condition.
(E) Comparison of dysregulated processes and
cell compartments in ccRCC tumor and in
ESRP2-knockdown PRPTECs. Each dot repre-
sents either a Gene Ontology (GO) (The Gene
Ontology Consortium, 2015) biological process or
a GO cell compartment. The axes show the
Z score fromMann-Whitney U test for change in the abundance of mRNAs of each GO term, with positive values representing overall upregulation of the GO term
and negative values representing downregulation. The x axis corresponds to dysregulation in ccRCC tumor relative to normal tissue (CAGEKID dataset), and the
y axis corresponds to dysregulation in ESRP2 knockdown (average of two shRNAs) relative to the Ctrl condition. GO terms that are significantly upregulated
(Z scoreR 3.5, red) or downregulated (Z score# 3.5, blue) in both ccRCC tumor and ESRP2-knockdown cells are highlighted.
(F) The mRNA abundance of genes that belong to both extracellular matrix (ECM) and endoplasmic reticulum lumen (ER) compartments (bottom) or genes that
belong to the tricarboxylic acid (TCA) cycle (top). The color gradient represents the average logarithm of fold change between tumor and normal tissue (based on
CAGEKID) or logarithm of fold change for each of the ESRP2 shRNA infections relative to control shRNA. The color map is shown on the right.
(G) Abundance of COLA1 after ESRP2 knockdown in PRPTECs, as measured by ELISA.
All error bars represent SD. *p < 0.05 (one-sided Wilcoxon test).
See also Figures S3 and S5.of apoptosis (Figure 4I). These observations confirmed that
PCBP2 enhances cell-cycle progression and proliferation in
ccRCC.
MBNL2 Is Essential for ccRCC Cells
Lastly, we investigated the dysregulation and the role of MBNL2
in ccRCC,which had exhibited a strong enhanced activity in both
CAGEKID and TCGAdatasets (Figure 2D).We noted thatMBNL2
mRNA is significantly upregulated only in the CAGEKID cohort,
with the TCGA cohort showing an overall consistent, albeit not
statistically significant, trend (Figure 5A). Therefore, we interro-gated MBNL2 protein levels using IHC as described earlier.
Measuring MBNL2 expression in a panel of 35 morphologically
normal and 76 tumor tissue samples from ccRCC patients
showed a strong overexpression in tumor cells (16.8-fold in-
crease for MBNL2, p < 7 3 108; Figures 5B and 5C), corrobo-
rating the predicted increase in its activity levels.
To study MBNL2 function, we inhibited the expression of
MBNL2 in 786-O and A-498 cells (Figure 5D), which resulted in
a global effect on the transcriptome, with significant overlap be-
tween genes dysregulated in the two cell lines (Figure S3C).
Given the well-characterized role ofMBNL2 in regulating splicingCell Reports 23, 1639–1650, May 8, 2018 1643
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Figure 4. PCPB2 Is Upregulated at Translational Levels in ccRCC and Contributes to the Cell-Cycle Progression
(A) PCBP2mRNA abundance does not show a significant change in ccRCC tumor compared tomatched normal kidney tissue samples. See Figure 3A for the plot
details.
(B) Comparison of protein abundance between ccRCC tumor (TM) and normal kidney (N) tissue for PCBP2, measured using tissue microarrays (TMAs), shows
upregulation in tumors. See the Supplemental Experimental Procedures for the definition of H-score. p values are based on t test.
(C) Representative TMA images for measuring the abundance of PCBP2 in normal and tumor tissues.
(D) Comparison of mRNA abundance change between tumor and normal tissues (CAGEKID dataset, y axis) and mRNA abundance change as a result of PCBP2
knockdown in HepG2 cells (x axis, average of two shRNAs).
(E) Representative pathways that are significantly enriched among the top 50 most downregulated genes after PCBP2 knockdown. The fraction of the 50 genes
that belong to each pathway is shown in parentheses, followed by enrichment p value (Fisher’s exact test). Pathway annotations are based on Reactome (Croft
et al., 2014).
(F) Correlation of the ccRCC-associated mRNA abundance of cell-cycle genes with the mRNA abundance of PCBP2 (solid bars) or inferred PCBP2 activity (open
bars). Correlations are calculated across 45matching pairs of tumor-normal tissues from the CAGEKID dataset. Only cell-cycle genes that are among the 50most
downregulated genes after PCBP2 knockdown are shown.
(G)Western blot analysis of PCBP2 protein in 786-O and A-498 cells after knockdown using two different siRNAs, as well as using a control (non-targeting) siRNA.
(H) Change in the proportion of cells in different cell-cycle phases after PCBP2 knockdown in 786-O and A-498 cells.
(I) Viability (left) and caspase-3/7 activity (right) after PCBP2 knockdown.
Values are normalized to control (non-targeting) siRNA in (H) and (I). Error bars in (B) represent SEM. Other error bars represent SD.
See also the Supplemental Experimental Procedures and Figure S4.(Charizanis et al., 2012), we first examined the splicing targets of
this protein and observed significant dysregulation of their tran-
script isoform distributions after MBNL2 knockdown (Fig-
ure S3D). Next, we examined the effect of MBNL2 knockdown
on its stability targets. Inference of mRNA stability from the
RNA-seq data revealed an overall destabilization of predicted
MBNL2-binding mRNAs after MBNL2 knockdown (Figure S3E),
consistent with a role of MBNL2 in stabilizing its targets. Interest-
ingly, MBNL2 knockdown partially reversed the gene expression
signature of ccRCC, leading to an overall decrease in the expres-
sion of genes that are upregulated in ccRCC (r = 0.11, p < 3 3
1062; Figure S3F). These genes are highly enriched for path-
ways with well-established roles in ccRCC, including the HIF-a
TF network (Harris, 2002), the FOXM1 TF network (Wu et al.,1644 Cell Reports 23, 1639–1650, May 8, 20182013; Xue et al., 2012), and the PLK1 signaling pathway (Ding
et al., 2011; Zhang et al., 2013) (Figure 5E). The HIF-a network
genes that showed the greatest downregulation after MBNL2
knockdown included vascular endothelial growth factor A
(VEGFA), a well-known angiogenic factor, along with four other
genes (Figure 5F). In agreement with a potential role of MBNL2
in regulating these genes, they showed strong correlation with
MBNL2 expression across the 45 tumor samples from the
CAGEKID dataset (Figure 5G), with VEGFA showing the stron-
gest correlation (r = 0.49, p < 3 3 104). Through a pull-down
assay using an antibody against MBNL2, we confirmed that
MBNL2 directly binds to VEGFA mRNA (Figure 5H), consistent
with a previously identified interaction between mouse Mbnl2
and the 30 UTR of Vegfa (Charizanis et al., 2012). We also
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Figure 5. MBNL2 Upregulation Enhances HIF-Responsive Gene Expression and Cell Proliferation Pathways in ccRCC
(A) The ccRCC-associated mRNA abundance change for MBNL2. See Figure 3A for the plot details.
(B) Comparison of protein abundance between ccRCC tumor (TM) and normal kidney (N) tissue for MBNL2, measured using TMAs. See the Supplemental
Experimental Procedures for the definition of H-score. p values are based on Student’s t test.
(C) Representative TMA images for measuring the abundance of MBNL2 in normal and tumor tissues.
(D) Western blot analysis of MBNL2 abundance in 786-O and A-498 cells infected with a control shRNA (Ctrl) or with two different shRNAs specifically targeting
MBNL2.
(E) Comparison of dysregulated pathways in ccRCC tumor and MBNL2-knockdown ccRCC cell lines. Each dot represents a pathway from the PID database
(Schaefer et al., 2009). The x axis shows theMann-Whitney U test Z score for up- or downregulation of pathways in ccRCC tumor versus normal tissue (CAGEKID
dataset), and the y axis shows the Z score for dysregulation of pathways after MBNL2 knockdown relative to control shRNA.
(F) Among genes that are upregulated in tumor (average log2 fold change R 1.5), the overlap of the HIF-a network genes (based on PID) with those that are
downregulated after MBNL2 knockdown (average log2 fold-change# 1.5) is shown.
(G) Comparison of the expression of HIF-a network genes with MBNL2 across 45 ccRCC tumors in the CAGEKID dataset. Each row represents a gene, and each
column represents a matching pair of tumor-normal tissues. Columns are sorted based on MBNL2 expression. The color gradient denotes log2 of fold change
between ccRCC tumor and normal tissue, with values transformed so that the average of each column becomes zero. Only the HIF-a network genes that are
upregulated in ccRCC tumor and downregulated in MBNL2-knockdown cells are shown.
(H) Interaction of VEGFA mRNA with MBNL2, as measured by qRT-PCR in an MBNL2 pull-down assay.
(I) Downregulation of MBNL2 after knockdown (left) leads to downregulation of VEGFA (right), as measured by qRT-PCR.
(J) Colony formation assay for 786-O and A-498 cells infected with a control shRNA (shCtrl) or with two different shRNAs that specifically inhibit MBNL2.
Representative images are shown on the left, and colony area measurements from independent experiments are shown using the bar plots (n = 3).
(K) Change in the cell-cycle distribution after MBNL2 knockdown in 786-O cells.
(L) Caspase-3/7 activity after MBNL2 knockdown.
Values are normalized to control (non-targeting) shRNA in (I-L). Error bars in (B) represent SEM. Other error bars represent SD.
See also the Supplemental Experimental Procedures and Figures S3 and S5.observed significant reduction of VEGFA mRNA levels after
MBNL2 knockdown (Figure 5I), corroborating a role of MBNL2
in stabilizing the VEGFA mRNA.
In addition, we observed that MBNL2 inhibition significantly
reduced the colony-forming ability of both 786-O and A-498 cells
(Figure 5J), in agreement with the downregulation of FOXM1 andPLK1 pathways, which regulate cell-cycle progression and cell
proliferation in ccRCC (Ding et al., 2011; Xue et al., 2012). Further
analysis of cell-cycle status revealed that knockdown of MBNL2
in 786-O cells impairs cell cycle and induces an increase in the
sub-G1 population of cells, indicative of increased apoptotic
cells (Figure 5K). Indeed, we observed an induction of activatedCell Reports 23, 1639–1650, May 8, 2018 1645
caspase-3/7 in MBNL2-deficient cells, confirming the activation
of the apoptosis pathway (Figure 5L).
DISCUSSION
By combining ccRCC expression profiles with a model of the
RBP-regulated stability programs (Ray et al., 2013), we identified
several RBPs that have significant roles in modulating the
ccRCC gene expression signature, affecting the abundance of
mRNAs in pathways that are critical to the development and pro-
gression of cancer. We investigated three RBPs with highly sig-
nificant cancer-associated activities—ESRP2, PCBP2 and
MBNL2—for their function and potential mechanisms of action
in ccRCC. PCBP2 is of particular interest, given that the mRNA
level of this protein is not different between ccRCC tumor and
normal kidney tissues. We observed a very significant increase
in the abundance of PCBP2 protein in ccRCC tumors, despite
a lack of change at the mRNA level, suggesting that this RBP
is potentially upregulated at the translation level, which is sup-
ported by data showing increased PBCP2 ribosome occupancy
in ccRCC. This candidate would be missed had we relied on dif-
ferential expression at the mRNA level for discovering RBPs with
a gene regulatory function in cancer. This example highlights the
value of inferring RBP activity levels based onmodeling the post-
transcriptional regulatory programs in order to identify RBPs
driving transcriptome aberrations. Interestingly, PCBP2 has
recently been shown to be upregulated at both the mRNA and
protein levels in glioma where its inhibition slowed down cancer
cell growth by impairing cell-cycle progression (Han et al.,
2013b). Results from our transcriptomic analysis of ccRCC tu-
mors and cell-cycle analysis of knockdown cells corroborate
the oncogenic function of PCBP2 shown in this report and sug-
gest that the expression of RBPs can be dysregulated by
different mechanisms in different tissues; e.g., at the transcrip-
tional level in glioma and at the post-transcriptional level in
ccRCC.
Our study has also highlighted ESRP2 as a putative tumor sup-
pressor in ccRCC with reduced activity levels in tumors. Sup-
porting our results, a recent report has shown that the ESRP2
function suppresses ccRCC progression (Mizutani et al., 2016).
ESRP2 expression is also associated with favorable prognosis
in ccRCC (Figure S5A). Moreover, suggesting a general tumor-
suppressive function for ESRP2, previous literature has reported
that the deficiency of this protein promotes epithelial-mesen-
chymal transition (EMT), a process with a central role in cancer
progression and metastasis (Shapiro et al., 2011; Warzecha
et al., 2009, 2010). In line with the fact that EMT involves the dys-
regulation and remodeling of ECM (Gonzalez and Medici, 2014),
we observed elevated expression of collagens, which are among
the major constituents of ECM (Frantz et al., 2010), following
ESRP2 suppression in kidney epithelial cells. Furthermore,
whereas previous studies have focused only on the splicing reg-
ulatory function of ESRP2, our data reveal that the functional
consequences of ESRP2 deficiency are broader than previously
recognized; involve dysregulation of its stability activity; and lead
to additional aberrations, including a metabolic shift toward the
Warburg-effect, a characteristic feature of ccRCC (Zaravinos
and Deltas, 2014).1646 Cell Reports 23, 1639–1650, May 8, 2018Finally, MBNL2 displayed significant elevated activities in
ccRCC in both the CAGEKID and TCGA datasets. MBNL2 plays
an important role in the differentiation of embryonic stem cells
(Han et al., 2013a), as well as in neuronal differentiation (Talia-
ferro et al., 2016). Although not previously linked to ccRCC,
MBNL2 expression increases themigratory capacity of lung can-
cer cells (Adereth et al., 2005), suggesting a role in metastasis.
Our IHC analyses also show that MBNL2 is upregulated in met-
astatic ccRCC tissues compared to primary tumors (Figure S5B).
Furthermore, MBNL2 positively regulates levels of colony-stimu-
lating factor receptor 1 (CSF1R) (Adereth et al., 2005), whose in-
hibition decreases the proliferation of renal cancer cells (Menke
et al., 2012). Corroborating these reports, our analysis of the
ccRCC transcriptome suggests an oncogenic function for
MBNL2, which is at least partly due to the effect of MBNL2 on
the abundance of cancer-associated transcripts and is sup-
ported by further functional validation in ccRCC cell lines. Spe-
cifically, we established that suppression of MBNL2 impairs
cell proliferation and activates the apoptosis pathway in renal
cancer cells.
PCBP2, MBNL2, and ESRP2 have widespread effects on the
transcriptome based on our knockdown experiments followed
by RNA-seq. Our analyses confirmed that the mRNAs that
have target sites in their 30 UTRs for these RBPs are enriched
in the altered transcriptome following knockdown experiments.
Of significance, we established that MBNL2 directly binds to
the mRNA that encodes VEGFA and is essential for maintaining
its expression in ccRCC cells. VEGFA is a prominent angiogenic
factor that plays important roles in cancer metastasis. In addition
to direct binding and dysregulation of VEGFA in MBNL2-knock-
down cells, we observed a significant correlation between
MBNL2 activity and the expression of VEGFA in tumor samples,
supporting the notion that the upregulation of MBNL2 leads to
higher levels of VEGFA. We note the potential clinical applica-
tions of this finding, given that VEGFA and downstream path-
ways are therapeutic targets in ccRCC (Riazalhosseini and
Lathrop, 2016).
In addition to the direct effects of RBPs, a large fraction of the
global remodeling of the transcriptome in our knockdown exper-
iments appears to reflect indirect downstream effects, since
many of the affected mRNAs do not have a binding site for the
RBPs. This widespread dysregulation may potentially stem
from the effect of RBPs on regulatory hubs, which can amplify
and propagate across thousands of genes. For example, in addi-
tion to direct targeting by MBNL2 (e.g., in the case of VEGFA),
downregulation of HIF-a network genes after inhibition of
MBNL2 can be a result of downregulation of the HIF-a TF itself.
Indeed, we observed that in A-498 cells, the mRNAs encoding
the HIF-1a and HIF-2a proteins, which share many transcrip-
tional targets in the HIF-a network (Scho¨del et al., 2011; Shino-
jima et al., 2007), are reproducibly downregulated after MBNL2
knockdown (Figure S5C). Similarly, in 786-O cells, which only ex-
press the full-length HIF-2a (Maxwell et al., 1999; Shinojima
et al., 2007), MBNL2 knockdown results in downregulation of
this gene (Figure S5C). This is further highlighted by a strong cor-
relation between the MBNL2 abundance/activity and the abun-
dance ofHIF-1/2-a transcripts in the ccRCC tumors (Figure S5D).
In addition, by analyzing genes that have a binding site for HIF-1a
but not for HIF-2a (Scho¨del et al., 2011), we found that these
genes are responsive to MBNL2 only in A-498 cells, which ex-
press full-length HIF-1a transcript (Shinojima et al., 2007). In
contrast, in 786-O cells, which do not express a full-length
HIF-1a transcript (Maxwell et al., 1999; Shinojima et al., 2007),
MBNL2 knockdown does not alter the expression of genes
that are specifically bound by HIF-1a (Figure S5E), further sup-
porting an indirect effect of MBNL2 on these genes that requires
modulation of HIF-a TFs. Genes that are specifically bound by
HIF-2a but not HIF-1a, on the other hand, were downregulated
after MBNL2 knockdown in both A-498 and 786-O cells, consis-
tent with the notion that HIF-2a is expressed and functional in
both of these cell lines (Shinojima et al., 2007). The importance
of hypoxia in progression of ccRCC and its driving role in cancer
metastasis, as extensively described previously (reviewed by
Keith et al., 2011), warrants the need for further studies to
delineate the mechanisms through which MBNL2 can directly
or indirectly modulate the expression of HIF-a TFs and their
downstream targets.
It is notable that the model of RBP-mediated stability network
that we used covers only 9% of all sequence-specific human
RBPs with known RNA-binding domains, and even a smaller
fraction of all human RBPs (Gerstberger et al., 2014). Therefore,
the actual landscape of RBP dysregulation in ccRCC is probably
more complex than the analysis presented here. Nonetheless,
our study presents a general framework for analysis of RBP sta-
bility programs in ccRCC and highlights the regulatory mecha-
nisms of the central pathways that underlie ccRCC progression,
including hypoxia signaling and the switch to aerobic glycolysis.
Given that these pathways are among the most attractive thera-
peutic targets for ccRCC (Riazalhosseini and Lathrop, 2016;
Srinivasan et al., 2015), our results may open new avenues for
targeted therapy in ccRCC. Similarly, our approach can be
used for systematic analysis of post-transcriptional gene regula-
tion in other cancers, and in other diseases in general.
EXPERIMENTAL PROCEDURES
Additional details on the experimental procedures and reagents used in
this study are provided in the Supplemental Experimental Procedures and
Table S2.
Expression Data and the Stability Code
Expression data were obtained for 45 pairs of ccRCC tumors and patient-
matched normal tissues from CAGEKID (Scelo et al., 2014) and for 72 pairs
of tumors and patient-matched normal tissues from TCGA (Cancer Genome
Atlas Research Network, 2013). Gene-level measurements (fragments per
kilobase per million [FPKM] for CAGEKID and RSEM-based transcript per
million [TPM] for TCGA) were used to calculate log10 of fold change between
each tumor and its patient-matched normal tissue (after adding a pseudocount
equal to 1% of the median of each sample). Gene symbols were mapped to
Ensembl v84 gene IDs, and genes with ambiguous ID mapping were
discarded.
We obtained the set of high-confidence stability targets of 35 RBPs from a
previous study (Ray et al., 2013), consisting of 3,483 mRNAs that contain at
least one functional binding site in their 30 UTR for at least one RBP. Of these,
3,376 genes had gene-level measurements in the CAGEKID dataset (1,151 for
the TCGA dataset). This stability code was converted to a 3,376 3 35 ‘‘bind-
ing’’ matrix B (Figure 1A), in which +1 and 1 indicate functional binding of
RBPs resulting in the stabilization and destabilization of the mRNA, respec-
tively, and in which zero indicates no functional binding.Modeling mRNA Stability and Inferring RBP Activity
For simplicity of modeling mRNA stability, we assume that all mRNA isoforms
encoded by each gene have the same decay rate. This assumption is reason-
able, considering that the stability code that we used consists of genes that
have no alternative 30 UTRs (Ray et al., 2013), and therefore, 30 UTR-mediated
regulation of mRNA stability should apply uniformly to all isoforms of each
gene. With this assumption, at steady state, the abundance of the mRNA for
gene g in tissue t can be expressed as:
½gt = rp;tðgÞ

rd;tðgÞ;
where rp,t and rd,t denote rates of production (transcription) and decay in tissue
t, respectively. Therefore, the logarithm of abundance can be expressed as:
log½gt = logrp;tðgÞ--logrd;tðgÞ= logrp;tðgÞ+ logsg;t ;
where sg,t represents the stability of mRNA g in tissue t, defined as the multi-
plicative inverse of decay rate. We model the mRNA stability as the combina-
torial effect of binding of RBPs to the 30 UTR, similar to previous studies on
modeling gene expression based on TF binding (Lee and Bussemaker, 2010):
sg;t =
Y
i
ai;t
bðg;iÞ
Here, ai,t represents the activity of RBP i in tissue t, and b(g,i) denotes the func-
tional binding of RBP i to the 30 UTR of mRNA g (+1 for stabilizing binding, 0 for
no binding, and 1 for destabilizing binding, as indicated earlier). Therefore,
the abundance of g can be modeled as:
log½gt = logrp;tðgÞ+
X
i
logðai;tÞ3bðg; iÞ;
and the differential abundance of g between patient-matched tumor and
normal tissue can be modeled as:
Dlog½g=DlogrpðgÞ+
X
i
DlogðaiÞ3bðg; iÞ;
where Dlog(ai) is the differential activity of RBP i in tumor versus normal tissue.
We assume that the differential rate of transcription is independent of the dif-
ferential rate of decay (Alkallas et al., 2017), allowing us to estimate the values
of Dlog(ai) for the RBPs in each tumor-normal tissue pair by regression, using
Dlog [g] (logarithm of fold change) as the response variable and the matrix B
(RBP binding matrix) as the covariate. In other words, we assume that Dlog
rp(g) is not correlated with Dlog rd,t(g), and, therefore, the regression coeffi-
cients in Dlog [g] Si Dlog(ai) are equal to the regression coefficients in the
full model. For each tumor-normal tissue pair, least-squares regression was
performed with bootstrapping to estimate the RBP differential activities as
well as the confidence intervals. Specifically, we repeated the regression
1,000 times, each time sampling 3,376 mRNAs for CAGEKID (or 1,151 mRNAs
for TCGA) with replacement. The average (m) and SD (s) of regression coeffi-
cients were estimated from the 1,000 bootstrapped regressions and were
used to calculate a Z score in each tissue for each RBP as m/s. This Z score
forms the core measurement of inferred differential RBP activities in this
article.
To estimate the overall increase or decrease of RBP activities across all in-
dividuals, we calculated the Student’s t score of the set of Z scores obtained
for each RBP across the individuals. A large positive t score indicates that the
inferred Z scores are overall above zero across the individuals, and a large
negative t score indicates that the inferred Z scores are overall below zero.
All data files and scripts for measuring RBP activities are available at http://
csg.lab.mcgill.ca/sup/ccRCC_RBP/.
TMAs
TMA specimens used in this study have been described previously (Xu et al.,
2013). Immunohistochemistry (IHC) was performed using a Ventana auto-
mated system and the iVIEW DAB Detection Kit (Ventana Medical Systems,
Tucson, AZ, USA) at the IHC laboratory of McGill University Health Centre
(MUHC). See the Supplemental Experimental Procedures for additional
details.Cell Reports 23, 1639–1650, May 8, 2018 1647
Cell Culture
The established renal cancer cell lines 786-O and A-498 and the non-tumori-
genic PRPTEC cells were purchased from the American Type Culture Collec-
tion (ATCC; Rockville, MD, USA). These cell lines were cultured according to
the recommendations of ATCC in the appropriate cell culture media and
were incubated at 37C in a humidified incubator with 5% CO2.
Real-Time qPCR
For each sample, 1 mg total RNA was used for reverse transcription followed
by real-time qPCR reactions in triplicates. Expression of each mRNA was
normalized to the expression of the housekeeping gene actin and was re-
ported as 2DDCt. See the Supplemental Experimental Procedures for addi-
tional details.
RBP Knockdown
The shRNA-mediated knockdown (KD) of ESRP2 and MBNL2 was carried out
based on previously described protocols (Papadakis et al., 2015). Briefly, lentivi-
ral supernatants producedbyHEK293Tcells were used to infect cells. In parallel,
supernatant harboring pLKO.1wasgenerated and usedascontrol. Infectedcells
were selectedwith puromycin (2 mg/mL, Sigma) for 4–5 days. For PCBP2 knock-
down, reverse transfection with 35 nM siRNA using Lipofectamine RNAiMAX
(Invitrogen) was performed according to the manufacturer’s instructions.
Western Blot Analysis
Protein extraction and western blotting from cell lines were performed as pre-
viously described (Jandaghi et al., 2016). See the Supplemental Experimental
Procedures for additional details.
ESRP2- and MBNL2-Knockdown RNA-Seq
Total RNA was extracted from cells infected withMBNL2 or ESRP2 or control
shRNAs, using the miRNeasy Mini Kit (QIAGEN) according to the supplier pro-
tocols. The RNA was used to generate rRNA-depleted first-strand cDNA li-
braries using TruSeq Stranded Total RNA-LT (Ribo-Zero Gold, Illumina). The
libraries were sequenced on a HiSeq 2000 platform, producing a minimum
of 50 million paired-end 100-bp reads per sample. Reads were mapped to
the GRCh37 human genome assembly using STAR (Dobin et al., 2013). Num-
ber of reads mapping to each gene was calculated using HTSeq (Anders et al.,
2015) based on gene annotations from GENCODE v19 (Harrow et al., 2012),
and genes with fewer than an average of 10 reads per sample were discarded.
The variance-stabilized logarithm of read counts was calculated using DESeq
(Anders and Huber, 2010), and the values were normalized to have an average
of zero for each sample. The effect of knockdown on the abundance of each
mRNA was calculated as the difference of normalized values between KD
and control shRNA samples, representing logarithm of fold change between
the two conditions.
For functional enrichment analysis, GeneOntology (GO) (TheGeneOntology
Consortium, 2015) and pathway interaction database (PID) (Schaefer et al.,
2009) annotations were obtained from ConsensusPathDB (Kamburov et al.,
2011). The annotations were intersected with the expression measurements,
and genes with no annotations were removed from the analysis. To measure
the overall upregulation or downregulation of a particular gene category (i.e.,
a GO biological process, GO cell compartment, or PID pathway), the distribu-
tion of logarithm of fold change of genes that belonged to that category was
compared to the distribution of logarithm of fold change of genes that did
not belong to that category, using the Mann-Whitney U test. The p values
were corrected for multiple testing using the Benjamini-Hochberg procedure.
RNA-seq data are deposited under accession number GEO: GSE83999.
RBP Immunoprecipitation
MBNL2 immunoprecipitation was performed using the Magna RIP Kit (Milli-
pore) according to the manufacturer’s protocol with slight modifications, as
explained in the Supplemental Experimental Procedures. RNA abundances
were normalized to the 18S rRNA as the internal control.
Pro-Collagen I Alpha 1 Detection by ELISA
An ELISA Kit from Abcam was used to quantify human COL1A1 protein in cell
lysate. Total protein of the non-tumorigenic PRPTEC cells was isolated using1648 Cell Reports 23, 1639–1650, May 8, 2018M-PER lysis buffer and quantified using the BCA Protein Assay. 0.1 mg total
protein and the antibody cocktail were loaded into each well of the 96-well
plate and shaken gently for 1 hr at room temperature. Each well was washed
four times with wash buffer and incubated 10 min with TMB ELISA Substrate.
To detect horseradish peroxidase (HRP) activity, stop solution was added into
each well, and the optical density (OD) was recorded at 450 nm using Tecan
Infinite Microplate Reader.
Colony-Formation Assay
Cells infected with shRNA constructs were trypsinized and plated in a 6-well
plate as single cells (2,000 cells per well), and colony formation was assessed
after 10 days. See the Supplemental Experimental Procedures for additional
details.
Fluorescence-Activated Cell Sorting Cell-Cycle Analysis
After 48 hr, knockdown and control cells were harvested with Accutase cell
detachment solution (Sigma) and washed with cold PBS. Cold Nicoletti buffer
(Nicoletti et al., 1991) was used for staining, and the DNA content of single
nuclei was analyzed by BD FACSCanto II Flow Cytometry Analyzer Systems
with collection of at least 10,000 events for each sample. The experiments
were performed in triplicates.
Cell Viability and Caspase-3/7 Activity
Cell viability and apoptosis induction were examined using CellTiter-Glo and
Caspase-Glo 3/7 Assay Kits (Promega), respectively, 48 hr (apoptosis) or
96 hr (cell viability) after transfection (PCBP2) or puromycin cell selection
(MBNL2), as previously described (Jandaghi et al., 2016).
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-seq data generated in this study and re-
ported in this paper is GEO: GSE83999. Additional data files are available at
http://csg.lab.mcgill.ca/sup/ccRCC_RBP/.
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